• Abreu-Mota T, Hagen KR, Cooper K, Jahrling PB, Tan G, Wirblich C, Johnson RF, Schnell MJ. 2018. Non-neutralizing antibodies elicited by recombinant lassa-rabies vaccine are critical for protection against lassa fever. Nat Commun, 9:4223.

  • Ahmad W, Li Y, Guo Y, Wang X, Duan M, Guan Z, Liu Z, Zhang M. 2017. Rabies virus co-localizes with early (rab5) and late (rab7) endosomal proteins in neuronal and sh-sy5y cells. Virol Sin, 32:207-215.

  • Allegra A, Di Gioacchino M, Tonacci A, Musolino C, Gangemi S. 2020. Immunopathology of sars-cov-2 infection:Immune cells and mediators, prognostic factors, and immune-therapeutic implications. Int J Mol Sci, 21.

  • Andrianaivoarimanana V, Telfer S, Rajerison M, Ranjalahy MA, Andriamiarimanana F, Rahaingosoamamitiana C, Rahalison L, Jambou R. 2012. Immune responses to plague infection in wild rattus rattus, in madagascar:A role in foci persistence? PLoS One, 7:e38630.

  • Chabalgoity JA, Baz A, Rial A, Grille S. 2007. The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytokine Growth Factor Rev, 18:195-207.

  • Chan JF, Siu GK, Yuan S, Ip JD, Cai JP, Chu AW, Chan WM, Abdullah SMU, Luo C, Chan BP, Yuen TT, Chen LL, Chik KK, Liang R, Cao H, Man Poon VK, Chan CC, Leung KH, Tam AR, Tsang OT, Chan JM, To WK, Lam BH, Lee LK, Lo HW, Wong IT, Leung JS, Wong EY, Chu H, Yip CC, Cheng VC, Chan KH, Tse H, Lung DC, Ng KH, Au AK, Hung IF, Yuen KY, To KK. 2022. Probable animal-to-human transmission of sars-cov-2 delta variant ay.127 causing a pet shop-related covid-19 outbreak in hong kong. Clin Infect Dis.

  • Chen C, Zhang CG, Li RM, Wang ZM, Yuan YM, Li HQ, Fu ZF, Zhou M, Zhao L. 2019. Monophosphoryl-lipid a (mpla) is an efficacious adjuvant for inactivated rabies vaccines. Viruses-Basel, 11.

  • Cheng SMS, Mok CKP, Leung YWY, Ng SS, Chan KCK, Ko FW, Chen C, Yiu K, Lam BHS, Lau EHY, Chan KKP, Luk LLH, Li JKC, Tsang LCH, Poon LLM, Hui DSC, Peiris M. 2022. Neutralizing antibodies against the sars-cov-2 omicron variant ba.1 following homologous and heterologous coronavac or bnt162b2 vaccination. Nat Med, 28:486-489.

  • Chi H, Wang Y, Li E, Wang X, Wang H, Jin H, Han Q, Wang Z, Wang X, Zhu A, Sun J, Zhuang Z, Zhang L, Ye J, Wang H, Feng N, Hu M, Gao Y, Zhao J, Zhao Y, Yang S, Xia X. 2022. Inactivated rabies virus vectored mers-coronavirus vaccine induces protective immunity in mice, camels, and alpacas. Front Immunol, 13:823949.

  • Cliquet F, Aubert M, Sagne L. 1998. Development of a fluorescent antibody virus neutralisation test (favn test) for the quantitation of rabies-neutralising antibody. J Immunol Methods, 212:79-87.

  • Collier DA, Ferreira I, Kotagiri P, Datir RP, Lim EY, Touizer E, Meng B, Abdullahi A, Collaboration C-NBC-, Elmer A, Kingston N, Graves B, Le Gresley E, Caputo D, Bergamaschi L, Smith KGC, Bradley JR, Ceron-Gutierrez L, Cortes-Acevedo P, Barcenas-Morales G, Linterman MA, McCoy LE, Davis C, Thomson E, Lyons PA, McKinney E, Doffinger R, Wills M, Gupta RK. 2021. Age-related immune response heterogeneity to sars-cov-2 vaccine bnt162b2. Nature, 596:417-422.

  • da Fontoura Budaszewski R, Hudacek A, Sawatsky B, Kramer B, Yin X, Schnell MJ, von Messling V. 2017. Inactivated recombinant rabies viruses displaying canine distemper virus glycoproteins induce protective immunity against both pathogens. J Virol, 91.

  • Dai L, Gao GF. 2021. Viral targets for vaccines against covid-19. Nat Rev Immunol, 21:73-82.

  • Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C. 2020. Development of an inactivated vaccine candidate for sars-cov-2. Science, 369:77-81.

  • Guo L, Wang G, Wang Y, Zhang Q, Ren L, Gu X, Huang T, Zhong J, Wang Y, Wang X, Huang L, Xu L, Wang C, Chen L, Xiao X, Peng Y, Knight JC, Dong T, Cao B, Wang J. 2022. Sars-cov-2-specific antibody and t-cell responses 1 year after infection in people recovered from covid-19:A longitudinal cohort study. Lancet Microbe, 3:e348-e356.

  • Hoffmann M, Zhang L, Krüger N, Graichen L, Kleine-Weber H, Hofmann-Winkler H, Kempf A, Nessler S, Riggert J, Winkler MS, Schulz S, Jäck HM, Pöhlmann S. 2021. Sars-cov-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Rep, 35:109017.

  • Huang Y, Pantaleo G, Tapia G, Sanchez B, Zhang L, Trondsen M, Hovden AO, Pollard R, Rockstroh J, Okvist M, Sommerfelt MA. 2017. Cell-mediated immune predictors of vaccine effect on viral load and cd4 count in a phase 2 therapeutic hiv-1 vaccine clinical trial. EBioMedicine, 24:195-204.

  • Jin H, Jiao C, Cao Z, Huang P, Chi H, Bai Y, Liu D, Wang J, Feng N, Li N, Zhao Y, Wang T, Gao Y, Yang S, Xia X, Wang H. 2021. An inactivated recombinant rabies virus displaying the zika virus prm-e induces protective immunity against both pathogens. PLoS Negl Trop Dis, 15:e0009484.

  • Jin H, Bai Y, Wang J, Jiao C, Liu D, Zhang M, Li E, Huang P, Gong Z, Song Y, Xu S, Feng N, Zhao Y, Wang T, Li N, Gao Y, Yang S, Zhang H, Li Y, Xia X, Wang H. 2022. A bacterium-like particle vaccine displaying zika virus prm-e induces systemic immune responses in mice. Transbound Emerg Dis, 69:e2516-e2529.

  • Kim YI, Kim SG, Kim SM, Kim EH, Park SJ, Yu KM, Chang JH, Kim EJ, Lee S, Casel MAB, Um J, Song MS, Jeong HW, Lai VD, Kim Y, Chin BS, Park JS, Chung KH, Foo SS, Poo H, Mo IP, Lee OJ, Webby RJ, Jung JU, Choi YK. 2020. Infection and rapid transmission of sars-cov-2 in ferrets. Cell Host Microbe, 27:704-709.e702.

  • Kurup D, Wirblich C, Ramage H, Schnell MJ. 2020. Rabies virus-based covid-19 vaccine coravax™ induces high levels of neutralizing antibodies against sars-cov-2. NPJ Vaccines, 5:98.

  • Kurup D, Malherbe DC, Wirblich C, Lambert R, Ronk AJ, Zabihi Diba L, Bukreyev A, Schnell MJ. 2021. Inactivated rabies virus vectored sars-cov-2 vaccine prevents disease in a syrian hamster model. PLoS Pathog, 17:e1009383.

  • Lassauniere R, Polacek C, Frische A, Boding L, Saekmose SG, Rasmussen M, Fomsgaard A. 2022. Neutralizing antibodies against the sars-cov-2 omicron variant (ba.1) 1 to 18 weeks after the second and third doses of the bnt162b2 mrna vaccine. JAMA Netw Open, 5:e2212073.

  • Li E, Yan F, Huang P, Chi H, Xu S, Li G, Liu C, Feng N, Wang H, Zhao Y, Yang S, Xia X. 2020. Characterization of the immune response of mers-cov vaccine candidates derived from two different vectors in mice. Viruses, 12.

  • Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, Fan J, Song L, Tong Y, Fan H. 2022. Covid-19 vaccine development:Milestones, lessons and prospects. Signal Transduct Target Ther, 7:146.

  • Liu J, Liao M, Yan Y, Yang H, Wang H, Zhou J. 2020. Rabies virus phosphoprotein p5 binding to becn1 regulates self-replication by becn1-mediated autophagy signaling pathway. Cell Commun Signal, 18:153.

  • Lou F, Li M, Pang Z, Jiang L, Guan L, Tian L, Hu J, Fan J, Fan H. 2021. Understanding the secret of sars-cov-2 variants of concern/interest and immune escape. Front Immunol, 12:744242.

  • Lourenc Correia Moreira B, Aparecida Pereira L, Lappas Gimenez AP, Minor Fernandes Inagaki J, Raboni SM. 2019. Development and validation of a real-time rt-pcr assay for the quantification of rabies virus as quality control of inactivated rabies vaccines. J Virol Methods, 270:46-51.

  • Lundstrom K. 2020. Application of viral vectors for vaccine development with a special emphasis on covid-19. Viruses, 12.

  • Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. 2019. Mrna as a transformative technology for vaccine development to control infectious diseases. Mol Ther, 27:757-772.

  • McAloose D, Laverack M, Wang L, Killian ML, Caserta LC, Yuan F, Mitchell PK, Queen K, Mauldin MR, Cronk BD, Bartlett SL, Sykes JM, Zec S, Stokol T, Ingerman K, Delaney MA, Fredrickson R, Ivančić M, Jenkins-Moore M, Mozingo K, Franzen K, Bergeson NH, Goodman L, Wang H, Fang Y, Olmstead C, McCann C, Thomas P, Goodrich E, Elvinger F, Smith DC, Tong S, Slavinski S, Calle PP, Terio K, Torchetti MK, Diel DG. 2020. From people to panthera:Natural sars-cov-2 infection in tigers and lions at the bronx zoo. mBio, 11.

  • McGettigan JP, Naper K, Orenstein J, Koser M, McKenna PM, Schnell MJ. 2003. Functional human immunodeficiency virus type 1 (hiv-1) gag-pol or hiv-1 gag-pol and env expressed from a single rhabdovirus-based vaccine vector genome. J Virol, 77:10889-10899.

  • Muench H, Reed L. 1938. A simple method of estimating fifty percent endpoints.

  • Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU. 2020. Phase i/ii study of covid-19 rna vaccine bnt162b1 in adults. Nature, 586:589-593.

  • Munnink BBO, Sikkema RS, Nieuwenhuijse DF, Molenaar RJ, Munger E, Molenkamp R, van der Spek A, Tolsma P, Rietveld A, Brouwer M, Bouwmeester-Vincken N, Harders F, Hakze-van der Honing R, Wegdam-Blans MCA, Bouwstra RJ, GeurtsvanKessel C, van der Eijk AA, Velkers FC, Smit LAM, Stegeman A, van der Poel WHM, Koopmans MPG. 2021. Transmission of sars-cov-2 on mink farms between humans and mink and back to humans. Science, 371:172-177.

  • Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M, Lu Q, Li X, Sun Q, Liu J, Fan C, Huang W, Xu M, Wang Y. 2020. Establishment and validation of a pseudovirus neutralization assay for sars-cov-2. Emerg Microbes Infect, 9:680-686.

  • Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. 2020. Characterization of spike glycoprotein of sars-cov-2 on virus entry and its immune cross-reactivity with sars-cov. Nat Commun, 11:1620.

  • Phillips PL, Reyes L, Sampson EM, Murrell EA, Whitlock JA, Progulske-Fox A. 2018. Deletion of a conserved transcript pg_rs02100 expressed during logarithmic growth in porphyromonas gingivalis results in hyperpigmentation and increased tolerance to oxidative stress. PLoS One, 13:e0207295.

  • Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lorks V, Sikorski J, Hilker R, Becker D, Eller AK, Grutzner J, Boesler C, Rosenbaum C, Kuhnle MC, Luxemburger U, Kemmer-Bruck A, Langer D, Bexon M, Bolte S, Kariko K, Palanche T, Fischer B, Schultz A, Shi PY, Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully IL, Cutler M, Kalina W, Kyratsous CA, Cooper D, Dormitzer PR, Jansen KU, Tureci O. 2020. Covid-19 vaccine bnt162b1 elicits human antibody and th1 t cell responses. Nature, 586:594-599.

  • Schnell MJ, Mebatsion T, Conzelmann KK. 1994. Infectious rabies viruses from cloned cdna. EMBO J, 13:4195-4203.

  • Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z, Zhao Y, Liu P, Liang L, Cui P, Wang J, Zhang X, Guan Y, Tan W, Wu G, Chen H, Bu Z. 2020. Susceptibility of ferrets, cats, dogs, and other domesticated animals to sars-coronavirus 2. Science, 368:1016-1020.

  • Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, Gao G, Hu X, Zhang Y, Tong Z, Huang W, Liu WJ, Wu G, Zhang B, Wang L, Qi J, Feng H, Wang FS, Wang Q, Gao GF, Yuan Z, Yan J. 2020. A human neutralizing antibody targets the receptor-binding site of sars-cov-2. Nature, 584:120-124.

  • Shiota S, Mannen K, Matsumoto T, Yamada K, Yasui T, Takayama K, Kobayashi Y, Khawplod P, Gotoh K, Ahmed K, Iha H, Nishizono A. 2009. Development and evaluation of a rapid neutralizing antibody test for rabies. J Virol Methods, 161:58-62.

  • Sila T, Sunghan J, Laochareonsuk W, Surasombatpattana S, Kongkamol C, Ingviya T, Siripaitoon P, Kositpantawong N, Kanchanasuwan S, Hortiwakul T, Charernmak B, Nwabor OF, Silpapojakul K, Chusri S. 2022. Suspected cat-to-human transmission of sars-cov-2, thailand, july-september 2021. Emerg Infect Dis, 28:1485-1488.

  • Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, Simoneau CR, Ciling A, Khalid MM, Sreekumar B, Chen PY, Kumar GR, Montano M, Gascon R, Tsou CL, Garcia-Knight MA, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Soveg FW, George AF, Fang X, Maishan M, Matthay M, Morris MK, Wadford D, Hanson C, Greene WC, Andino R, Spraggon L, Roan NR, Chiu CY, Doudna JA, Ott M. 2022. Limited cross-variant immunity from sars-cov-2 omicron without vaccination. Nature, 607:351-355.

  • Thomson EC, Rosen LE, Shepherd JG, Spreafico R, Filipe AD, Wojcechowskyj JA, Davis C, Piccoli L, Pascall DJ, Dillen J, Lytras S, Czudnochowski N, Shah R, Meury M, Jesudason N, De Marco A, Li K, Bassi J, O'Toole A, Pinto D, Colquhoun RM, Culap K, Jackson B, Zatta F, Rambaut A, Jaconi S, Sreenu VB, Nix J, Zhang I, Jarrett RF, Glass WG, Beltramello M, Nomikou K, Pizzuto M, Tong L, Cameroni E, Croll TI, Johnson N, Di Iulio J, Wickenhagen A, Ceschi A, Harbison AM, Mair D, Ferrari P, Smollett K, Sallusto F, Carmichael S, Garzoni C, Nichols J, Galli M, Hughes J, Riva A, Ho A, Schiuma M, Semple MG, Openshaw PJM, Fadda E, Baillie JK, Chodera JD, Rihn SJ, Lycett SJ, Virgin HW, Telenti A, Corti D, Robertson DL, Snell G, Investigators IC, Consor C-GUC-U. 2021. Circulating sars-cov-2 spike n439k variants maintain fitness while evading antibody-mediated immunity. Cell, 184:1171-+.

  • van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, Avanzato VA, Bushmaker T, Flaxman A, Ulaszewska M, Feldmann F, Allen ER, Sharpe H, Schulz J, Holbrook M, Okumura A, Meade-White K, Pérez-Pérez L, Edwards NJ, Wright D, Bissett C, Gilbride C, Williamson BN, Rosenke R, Long D, Ishwarbhai A, Kailath R, Rose L, Morris S, Powers C, Lovaglio J, Hanley PW, Scott D, Saturday G, de Wit E, Gilbert SC, Munster VJ. 2020. Chadox1 ncov-19 vaccine prevents sars-cov-2 pneumonia in rhesus macaques. Nature, 586:578-582.

  • Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P. 2000. Development of th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol, 164:4507-4512.

  • Wallace RM, Undurraga EA, Blanton JD, Cleaton J, Franka R. 2017. Elimination of dog-mediated human rabies deaths by 2030:Needs assessment and alternatives for progress based on dog vaccination. Front Vet Sci, 4:9.

  • Wang H, Jin H, Feng N, Zheng X, Li L, Qi Y, Liang M, Zhao Y, Wang T, Gao Y, Tu C, Jin N, Yang S, Xia X. 2015a. Using rabies virus vaccine strain srv9 as viral vector to express exogenous gene. Virus Genes, 50:299-302.

  • Wang HL, Jin HL, Feng N, Zheng XX, Li L, Qi YL, Liang M, Zhao YK, Wang TC, Gao YW, Tu CC, Jin NY, Yang ST, Xia XZ. 2015b. Using rabies virus vaccine strain srv9 as viral vector to express exogenous gene. Virus Genes, 50:299-302.

  • Wang N, Shang J, Jiang S, Du L. 2020. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol, 11:298.

  • Wang S, Zhang C, Liang B, Wang W, Feng N, Zhao Y, Wang T, Guo Z, Yan F, Yang S, Xia X. 2022. Characterization of immune response diversity in rodents vaccinated with a vesicular stomatitis virus vectored covid-19 vaccine. Viruses, 14.

  • Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z, Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM, Nussenzweig MC, Hatziioannou T, Bieniasz PD. 2020. Escape from neutralizing antibodies by sars-cov-2 spike protein variants. Elife, 9.

  • Willet M, Kurup D, Papaneri A, Wirblich C, Hooper JW, Kwilas SA, Keshwara R, Hudacek A, Beilfuss S, Rudolph G, Pommerening E, Vos A, Neubert A, Jahrling P, Blaney JE, Johnson RF, Schnell MJ. 2015. Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses. J Infect Dis, 212 Suppl 2:S414-424.

  • Wirblich C, Coleman CM, Kurup D, Abraham TS, Bernbaum JG, Jahrling PB, Hensley LE, Johnson RF, Frieman MB, Schnell MJ. 2017. One-health:A safe, efficient, dual-use vaccine for humans and animals against middle east respiratory syndrome coronavirus and rabies virus. J Virol, 91.

  • Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. 2020. Cryo-em structure of the 2019-ncov spike in the prefusion conformation. Science, 367:1260-1263.

  • Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X. 2021. Safety and immunogenicity of an inactivated sars-cov-2 vaccine, bbibp-corv:A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis, 21:39-51.

  • Xu K, Gao P, Liu S, Lu S, Lei W, Zheng T, Liu X, Xie Y, Zhao Z, Guo S, Tang C, Yang Y, Yu W, Wang J, Zhou Y, Huang Q, Liu C, An Y, Zhang R, Han Y, Duan M, Wang S, Yang C, Wu C, Liu X, She G, Liu Y, Zhao X, Xu K, Qi J, Wu G, Peng X, Dai L, Wang P, Gao GF. 2022. Protective prototype-beta and delta-omicron chimeric rbd-dimer vaccines against sars-cov-2. Cell.

  • Yan F, Li E, Wang T, Li Y, Liu J, Wang W, Qin T, Su R, Pei H, Wang S, Feng N, Zhao Y, Yang S, Xia X, Gao Y. 2022. Characterization of two heterogeneous lethal mouse-adapted sars-cov-2 variants recapitulating representative aspects of human covid-19. Front Immunol, 13:821664.

  • Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, Bao L, Mo F, Li X, Huang Y, Hong W, Yang Y, Zhao Y, Ye F, Lin S, Deng W, Chen H, Lei H, Zhang Z, Luo M, Gao H, Zheng Y, Gong Y, Jiang X, Xu Y, Lv Q, Li D, Wang M, Li F, Wang S, Wang G, Yu P, Qu Y, Yang L, Deng H, Tong A, Li J, Wang Z, Yang J, Shen G, Zhao Z, Li Y, Luo J, Liu H, Yu W, Yang M, Xu J, Wang J, Li H, Wang H, Kuang D, Lin P, Hu Z, Guo W, Cheng W, He Y, Song X, Chen C, Xue Z, Yao S, Chen L, Ma X, Chen S, Gou M, Huang W, Wang Y, Fan C, Tian Z, Shi M, Wang FS, Dai L, Wu M, Li G, Wang G, Peng Y, Qian Z, Huang C, Lau JY, Yang Z, Wei Y, Cen X, Peng X, Qin C, Zhang K, Lu G, Wei X. 2020. A vaccine targeting the rbd of the s protein of sars-cov-2 induces protective immunity. Nature, 586:572-577.

  • Yen HL, Sit THC, Brackman CJ, Chuk SSY, Gu H, Tam KWS, Law PYT, Leung GM, Peiris M, Poon LLM, team H-Ss. 2022. Transmission of sars-cov-2 delta variant (ay.127) from pet hamsters to humans, leading to onward human-to-human transmission:A case study. Lancet, 399:1070-1078.

  • Zhang S, Hao M, Feng N, Jin H, Yan F, Chi H, Wang H, Han Q, Wang J, Wong G, Liu B, Wu J, Bi Y, Wang T, Sun W, Gao Y, Yang S, Zhao Y, Xia X. 2019. Genetically modified rabies virus vector-based rift valley fever virus vaccine is safe and induces efficacious immune responses in mice. Viruses, 11.

  • Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W. 2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored covid-19 vaccine in healthy adults aged 18 years or older:A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 396:479-488.